Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR 1,263.00
+2.20 (0.17%)
At close: Aug 29, 2025
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 85.45B INR in the quarter ending June 30, 2025, with 11.37% growth. This brings the company's revenue in the last twelve months to 334.26B, up 15.86% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
334.26B
Revenue Growth
+15.86%
P/S Ratio
3.15
Revenue / Employee
12.02M
Employees
27,811
Market Cap
1,051.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Hindustan Unilever | 639.28B |
| Infosys | 1,672.76B |
Dr. Reddy's Laboratories News
- 1 day ago - Top stocks to buy today: Stock recommendations for August 28, 2025 - check list - The Times of India
- 8 days ago - Nifty 50 top gainers and losers today, August 21: Cipla, Dr. Reddy’s Laboratories, Bajaj Finserv among top performers - Business Upturn
- 11 days ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 17 days ago - Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity - Business Upturn
- 21 days ago - Dr. Reddy’s Laboratorie gets EIR from USFDA for Telangana facility with VAI status - Business Upturn
- 21 days ago - Nifty top gainers and losers today, August 8: NTPC, Titan, Dr. Reddy’s Labs, HDFC Life among top performers - Business Upturn
- 23 days ago - Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt - The Times of India
- 25 days ago - Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New Revenues - Seeking Alpha